A biotech or medtech scaleup working out of a Brisbane biomedical precinct or a Sydney life sciences hub can look financially disciplined on paper and still misjudge how many months of genuine runway it has left. The trap is not reckless spending. It is treating money the business is owed as though it behaves like money already in the bank.
The R&D Tax Incentive is one of the strongest non-dilutive funding sources available to an early-stage life sciences company, and it should be. It rewards exactly the kind of spend a scaleup racks up every quarter: trial costs, prototype iterations, contract research, regulatory pathway work. What it does not do is arrive when the invoice does. The refund is calculated through the company’s annual tax return, which means the cash lands months after the spend it was meant to offset, sometimes well into the following financial year.
That gap sits quietly underneath most cash flow models until the runway gets tight. At that point it stops being a technicality and becomes the difference between raising capital on your own timeline and raising because the bank balance has made the decision for you.
The Burn Rate Looks Steady. The Cash Behind It Isn’t.
Most biotech and medtech businesses do not spend in a straight line. Trial milestones, batch manufacturing runs and regulatory submissions land in lumps, not monthly instalments. Layer an annual, lagging tax refund on top of that lumpy spend and the monthly cash position can swing from alarming to comfortable without anything in the underlying business actually changing. A founder watching the bank balance month to month can end up making decisions off a number that has more to do with refund timing than with the health of the business.
A trial that clears a recruitment milestone in one quarter and moves into a quieter data collection phase in the next can make monthly burn look like it is easing, when in fact the next wave of spend, a manufacturing scale-up, an additional site activation, or a regulatory filing, is already committed and will land as a single lump sum. Reading that quiet month as the new normal is how a founder ends up surprised by the following quarter’s numbers, even though nothing about the underlying trial plan has changed.
Counting the Refund the Moment It’s Earned, Not the Moment It Lands
The mistake we see most often in this pattern is not about the R&D Tax Incentive itself, it is about when a business counts it. Spend that qualifies in July gets pencilled into the runway model as good as banked, months before the tax return is even lodged, let alone assessed and paid. When the ATO’s processing takes longer than expected, or a lodgement slips, the runway the board has been working from is suddenly shorter than the board pack says. That is a hard conversation to have with a board or an investor, and it is an entirely avoidable one.
What a Careful Investor Sees Before You Do
Investors and lenders doing due diligence on a life sciences scaleup separate confirmed cash, the balance actually in the account or contractually committed, from anticipated cash such as a pending refund or an unpaid grant tranche, as one of their first steps. A founder who has already drawn that same line internally negotiates the next raise from a position of clarity. A founder who has not tends to discover the gap during the investor’s own diligence process, which is a considerably harder place to find it, and a worse position from which to negotiate terms.
Building a Runway That Doesn’t Depend on the Gap Closing
None of this is an argument against claiming the R&D Tax Incentive. It remains one of the better funding tools available to an eligible Australian life sciences business, and it should be claimed in full every year. It is an argument for keeping two numbers separate: the runway funded by cash already confirmed, and the upside that arrives once the refund clears. A rolling 13-week cash flow forecast built specifically to track confirmed versus anticipated cash makes that separation visible every week instead of once a year at tax time, and it turns the next raise into a planned event rather than a forced one.
In practice, that means running two lines side by side every week: the cash actually in the account or contractually locked in, and the cash reasonably expected but not yet cleared, refunds, grant tranches, milestone payments from a commercial partner. Decisions about hiring, trial timing or when to open the next raise get made off the first line. The second line is useful context, not a number to spend against.
Getting the timing right on a single non-dilutive funding source sounds like a small thing. For a scaleup running on a fixed pool of cash between raises, it is usually the difference between negotiating from strength and negotiating from need. That distinction is worth building into the forecast long before the next capital raise conversation starts.
Frequently asked questions
How does the R&D Tax Incentive refund timing affect a biotech scaleup’s cash runway?
The R&D Tax Incentive refund is calculated on spend incurred during the financial year, but it isn’t paid until the return is lodged and assessed, often close to a year after the money went out the door. If a scaleup counts that refund as available cash from the moment it qualifies rather than the moment it lands, its runway calculation will consistently overstate how long the business can actually operate.
What’s the difference between burn rate and cash runway for a medtech company?
Burn rate is how much cash the business uses each month. Runway is how many months of cash remain at that rate. The two numbers only tell the true story when every input, including anticipated grant or tax offset refunds, is timed to when it actually clears the bank account rather than when it was earned. A rolling 13-week cash flow forecast is the simplest way to keep both numbers honest.
Should a life sciences scaleup treat the R&D Tax Incentive as guaranteed funding?
No. It is one of the most reliable non-dilutive funding sources available to an eligible Australian company, but reliable and guaranteed are not the same thing. Lodgement timing, assessment delays and eligibility questions can all push the refund later than expected. Treat it as an accelerant to the runway once it clears, not as a line item the runway depends on to survive.
How do investors assess a biotech or medtech scaleup’s cash position before a raise?
Investors doing due diligence separate confirmed cash, the balance actually sitting in the account or contractually committed, from anticipated cash such as pending refunds or grant tranches. A founder who has already done this internally negotiates from a position of clarity. One who has not often discovers the gap during investor readiness diligence, which is a harder place to find it.
When should a biotech scaleup start planning its next capital raise?
Well before the confirmed cash runway, not the total runway including anticipated refunds, gets uncomfortably short. Raises take months to close even when the business fundamentals are strong. Businesses that leave the timing decision until the bank balance forces it tend to raise on worse terms. A structured capital raise preparation process starts with an honest read of that confirmed cash number.
What causes cash flow surprises in Australian biotech and medtech businesses?
The most common cause is not overspending, it is timing mismatches between when R&D and trial costs go out and when non-dilutive funding, tax offsets or milestone payments come in. Because these businesses often have lumpy, project-based spending rather than steady monthly costs, a standard monthly cash view can look fine right up until it is not. A rolling weekly forecast catches the gap earlier.
Is the R&D Tax Incentive refund paid before or after tax return lodgement?
After. The offset is calculated and applied as part of the company’s income tax return, so the refund can only be paid once that return is lodged and processed by the ATO. For a business with a standard financial year, that means R&D spend incurred early in the year is often not returned as cash until many months later, well into the following year in some cases.
Leave a Reply